Health experts slam US deal for large supply of virus drug The US government announced this week that it had an agreement with Gilead Sciences to make the bulk of their production of remdesivir for the next three months available to AmericansRead--
Brussels is in talks with Gilead Sciences to reserve doses of the drug remdesivir to combat coronavirus
SVB Leerink Weighs in on Gilead Sciences, Inc.’s Q1 2021 Earnings $GILD
The American pharmaceutical giant Gilead Sciences is coming under scrutiny for agreements that activists say will restrict global access to remdesivir, an experimental antiviral drug that has shown promise in treating COVID-19.
At least somebody was thinking ahead. This is how Gilead Sciences prepared for the coronavirus pandemic
NEWS: HHS has announced an agreement to secure large supplies of the drug remdesivir for the United States from Gilead Sciences through September, allowing American hospitals to purchase the drug in amounts allocated by HHS and state health departments.
After weeks of donating the antiviral drug remdesivir to hospitals with severely ill coronavirus patients, the drug’s maker, Gilead Sciences, announced that it has settled on a price: $390 per vial, which works out to be roughly $2,340 per treatment course
Gilead Sciences says their COVID-19 treatment will cost a U.S. patient with insurance $3,120:
A study funded by Gilead Sciences evaluating the use of its drug remdesivir to treat 53 seriously ill COVID-19 patients found that some got better. But there was no control group, so strong conclusions weren't possible.
BREAKING: Gilead Sciences says it's aware of positive data emerging from the study of remdesivir for the treatment of COVID-19, and that the trial has met its primary endpoint
Japan on Thursday approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, making it the country's first officially authorized drug to tackle the coronavirus disease.
After The Intercept’s story, Gilead Sciences announced that it has submitted a request to rescind the exclusive marketing rights to a promising coronavirus treatment.